TWST — Twist Bioscience Corp

Nasdaq · Health Care · Biotechnology · CIK 1581280 ·
Last close
$91.55
Market Cap
$5.70B
52W High
$105.47
52W Low
$48.00
ADV30
1,719,969
Next earnings
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 110,715,000 57,122,000 -38,658,000 -44,021,000 676,214,000 122,670,000 221,120,000
Dec 2025 103,698,000 53,972,000 -33,100,000 -30,507,000 638,085,000 148,591,000 181,990,000
Sep 2025 99,009,000 50,837,000 -29,934,000 -27,138,000 641,861,000 183,049,000 168,903,000
Jun 2025 96,057,000 51,297,000 -30,120,000 20,390,000 643,605,000 201,373,000 165,407,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-55,587,000
Investing CF
$-44,439,000
Financing CF
$11,836,000
CapEx
$-39,553,000
Dividends Paid
Buybacks
$-15,000
EPS Diluted TTM
$-1.33
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,394,106,000
Inventory
$33,515,000
Receivables
$87,448,000
ST Investments
$49,001,000
EBIT TTM
$-131,812,000
Pretax Income TTM
$-80,532,000
Interest Exp TTM
$0
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$409,479,008
EBITDA
$-109,835,000
Free Cash Flow
$-58,482,500
Enterprise Value
$5,626,408,960
Total Cash
$171,671,008
Total Debt
$110,841,000
Shares Out
62,271,314
Trailing EPS
$-1.32
Book Value
$7.32
ROE
-18.2%
ROA
-12.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 376,572,000 -136,259,000 -77,670,000 641,861,000 168,903,000 -47,628,000
Sep 2024 312,974,000 -175,901,000 -208,726,000 614,323,000 141,634,000 -64,094,000
Sep 2023 245,109,000 -206,903,000 -204,618,000 776,403,000 152,971,000 -142,474,000
Sep 2022 203,565,000 -249,021,000 -217,863,000 961,378,000 171,993,000 -124,385,000

TTM Snapshot

Revenues TTM
$170,177,000
NetIncome TTM
$-117,165,000
OpCashFlow TTM
$0
Assets (Latest)
$641,861,000
Forward EPS
$-0.85

Peers — same industry

TickerNameMarket CapLastDaily %
SRRK Scholar Rock Holding Corp $5.67B $47.29
CGON CG Oncology, Inc. $6.28B $71.19
CRSP CRISPR Therapeutics AG $4.73B $47.99
IBRX ImmunityBio, Inc. $7.51B $7.17
PCVX Vaxcyte, Inc. $7.81B $54.08

News headlines (Yahoo Finance, 1h cache)

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
2026-07-28 12:50 · Yahoo
Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains?
2026-07-28 10:55 · Yahoo
Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market
2026-07-27 12:00 · Yahoo
Twist Bioscience (TWST) Stock Looks Overvalued Even With Strong Growth Hopes
2026-07-26 03:18 · Yahoo
Twist Bioscience (TWST) Surged on Strong Results and AI Drug Discovery Demand
2026-07-24 16:16 · Yahoo
Cathie Wood Dumps $39 Million Worth of AMD Stock
2026-07-20 16:06 · Yahoo
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?
2026-07-19 20:32 · Yahoo
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
2026-07-15 12:00 · Yahoo
Cathie Wood’s ARK Invest Doubles Down On Circle In Two Funds At Once, Trims Robinhood Again
2026-07-15 11:41 · Yahoo
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
2026-07-14 09:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.